[National Institutes of Health 2021 Grant]; psilcoybin in the treatment of tobacco use disorder…
“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University.
Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators of treatment response. We hypothesize that psilocybin will be associated with improved cognitive control and decreased anticipation of withdrawal relief (from smoking) 1 day after the target quit date, which will be associated with greater 7-day point-prevalence abstinence at 12- month follow-up… [Johns Hopkins University in Maryland.]
Original Article (NIH Report and Axios):
5-HT2A agonist psilocybin in the treatment of tobacco use disorder & The science of psychedelic therapy breaks on through
Artwork Fair Use: MRaccine